Allocation to and type of second- and third-line treatments
| Second-line | Third-line | |||
| EB arm | PGB arm | EB arm | PGB arm | |
| Patients | 108 | 111 | 108 | 111 |
| Radiation therapy only | 4 (4) | 3 (3) | 3 (3) | 3 (3) |
| Any systemic treatment | 62 (57) | 70 (63) | 40 (37) | 34 (31) |
| EGFR-TKI | 3 (3) | 22 (20) | 3 (3) | 11 (10) |
| Mono chemotherapy | 15 (14) | 36 (32) | 30 (28) | 20 (18) |
| Docetaxel | 1 (1) | 7 (6) | 8 (7) | 7 (6) |
| Pemetrexed | 6 (6) | 26 (23) | 12 (11) | 8 (7) |
| Gemcitabine | 4 (4) | 0 (0) | 2 (2) | 0 (0) |
| Other | 4 (4) | 3 (3) | 8 (7) | 5 (5) |
| Combination chemotherapy | 44 (41) | 12 (11) | 7 (6) | 3 (3) |
| Cisplatinum-based | 24 (22) | 7 (6) | 2 (2) | 2 (2) |
| Carboplatinum-based | 20 (19) | 5 (5) | 3 (3) | 1 (1) |
Data are presented as n or n (%). EB: erlotinib/bevacizumab; PGB: cisplatin/gemcitabine/bevacizumab; EGFR-TKI: epidermal growth factor receptor tyrosine kinase inhibition.